European Clinics in Obstetrics and Gynaecology

, Volume 2, Issue 2, pp 77–81 | Cite as

Fertility preservation strategies in women undergoing chemotherapy for haematological malignancy

  • M. Huser
  • E. Jurankova
  • I. Crha
  • P. Ventruba
  • R. Hudecek
  • J. Zakova
  • L. Smardova
  • Z. Kral
Clinical Review


As one of the basic modalities of oncological therapy, chemotherapy usually leads to permanent consequences. Infertility is one of the most common consequences resulting from irreversible gonadal damage. The potentially effective method of reproductive function protection in women undergoing chemotherapy for haematological malignancy is administration of GnRH analogues during chemotherapy by creating pre-pubertal hormonal milieu. The other useful methods are the cryopreservation of oocytes and ovarian tissue from patients undergoing anti-cancer therapy. The presented OvarOnko project sets the primary target to verify the potential protective effect of GnRH analogues to protect ovarian tissue over the course of three different chemotherapy regimens in female patients with childbearing potential who suffer from Hodgkin’s lymphoma (HL). Another goal of the project is to work out practical conditions and working procedures for the development of the method of the cryopreservation of oocytes and ovarian tissue. The major outcomes of the project will be the verification of efficacy or the lack of efficacy of GnRH analogues in the ovarian function protection and the elaboration of practical conditions and working procedures allowing inclusion of the methods of cryopreservation of oocytes and ovarian tissue in services provided to our patients before anti-cancer treatment. The costs of the two methods of ovarian function protection will be compared. The differences in ovarian response between the patients with HL and non-oncological patients recorded in the register of therapeutic cycles of assisted reproduction will be identified using data-mining methods.


Infertility Chemotherapy Assisted reproduction Cryopreservation GnRH analogues Hodgkin disease 



This work is supported by Internal Grant Agency (IGA) of the Ministry of Health of the Czech Republic-No. NR/8469-3.


  1. 1.
    Lutchman Singh K, Davies M, Chatterjee R (2005) Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 11:69–89PubMedCrossRefGoogle Scholar
  2. 2.
    Kim SS (2006) Fertility preservation in female cancer patients: current developments and future directions. Fertil Steril 85(1):1–11PubMedCrossRefGoogle Scholar
  3. 3.
    Goswami D, Conway GS (2005) Premature ovarian failure. Hum Reprod Update 11(4):391–410PubMedCrossRefGoogle Scholar
  4. 4.
    Ataya K, Rao LV, Laurence E (1995) Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in Rhesus monkeys. Biol Reprod 8:86–92Google Scholar
  5. 5.
    Crha I, Ventruba P, Huser M, Žáková J (2002) Cryo-preservation of semen prior to anticancer therapy—7 years of experiences. Ces Gynek 67:324–328Google Scholar
  6. 6.
    Tucker M, Morton P, Liebermann J (2004) Human oocyte cryopreservation: a valid alternative to embryo cryopreservation? Eur J Obstet Gynecol Reprod Biol 113(suppl 1):24–27CrossRefGoogle Scholar
  7. 7.
    Borini A, Bonu MA, Coticchio G, Bianchi V, Cattoli M, Flamigni C (2004) Pregnancies and births after oocyte cryopreservation. Fertil Steril 82(3):601–605PubMedCrossRefGoogle Scholar
  8. 8.
    Marrs RP, Greene J, Stone BA (2004) Potential factors affecting embryo survival and clinical outcome with cryopreserved pronuclear human embryos. Am J Obstet Gynecol 190(6):1766–1771PubMedCrossRefGoogle Scholar
  9. 9.
    Oktay K, Sonmezer M (2004) Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation. Hum Reprod 19(3):477–480PubMedCrossRefGoogle Scholar
  10. 10.
    Sonmezer M, Shamonki MI, Oktay K (2005) Ovarian tissue cryopreservation: benefits and risks. Cell Tissue Res 322(1):125–132PubMedCrossRefGoogle Scholar
  11. 11.
    Donnez J, Dolmans MM, Delmylle D (2004) Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 364:1405–1410PubMedCrossRefGoogle Scholar
  12. 12.
    Meirow D, Levron J (2005) Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 353(3):318–321PubMedCrossRefGoogle Scholar
  13. 13.
    Schilsky R, Sherins R, Hubbard S (1981) Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin’s disease. Am J Med 71:552–556PubMedCrossRefGoogle Scholar
  14. 14.
    Blumenfeld Z (2002) Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and-B as markers. Mol Cell Endocrinol 187:93–105PubMedCrossRefGoogle Scholar
  15. 15.
    Schweppe KW (2005) Guidelines for the use of GnRH-analogues in the treatment of endometriosis. Zentralbl Gynakol 127(5):308–313PubMedCrossRefGoogle Scholar
  16. 16.
    Mardešič T, Šnajderová M (2004) Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy. Eur J Gynaecol Oncol 25(1):90–92PubMedGoogle Scholar
  17. 17.
    Blumenfeld Z (2002) Fertility after treatment for Hodgkin’s disease. Ann Oncol 13(Suppl 1):138–147PubMedGoogle Scholar
  18. 18.
    Dann EJ, Epelbaum R, Avivi I, Ben Shahar M, Haim N, Rowe JM, Blumenfeld Z (2005) Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod 20(8):2247–2249PubMedCrossRefGoogle Scholar
  19. 19.
    Huser M, Crha I, Hudecek R, Ventruba P, Zakova J, Smardova L (2006) Gonadal protection with GnRH analogues during chemotherapy-cytotoxic dose derived cohort study (OVARONKO). Gynecol Endocrinol 22(suppl 1):152–153Google Scholar
  20. 20.
    Johnson J, Tilly JT (2005) Germline stem cells and follicular renewal on the postnatal mammalian ovary. Nature 428:145–150CrossRefGoogle Scholar
  21. 21.
    Gosden RG (2005) Prospects for oocyte banking and in vitro maturation. J Natl Cancer Inst Monogr 34:60–63PubMedCrossRefGoogle Scholar
  22. 22.
    Crha I (2004) Reproductive function protection. In: Adam K (ed) General oncology, 2nd edn. Grada, pp 765–784Google Scholar
  23. 23.
    Schmidt KL, Andersen CY, Loft A, Byskov AG, Ernst E, Andersen AN (2005) Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod 20(12):3539–3546PubMedCrossRefGoogle Scholar
  24. 24.
    Schrader M, Heicappell R, Muller M (2001) Impact of chemotherapy on male fertility. Onkologie 24:326–330PubMedCrossRefGoogle Scholar

Copyright information

© European Board and College of Obstetrics and Gynaecology 2006

Authors and Affiliations

  • M. Huser
    • 1
  • E. Jurankova
    • 1
  • I. Crha
    • 1
  • P. Ventruba
    • 1
  • R. Hudecek
    • 1
  • J. Zakova
    • 1
  • L. Smardova
    • 2
  • Z. Kral
    • 2
  1. 1.Department of Gynaecology and ObstetricsUniversity Hospital BrnoBrnoCzech Republic
  2. 2.Department of Internal Medicine and HematooncologyUniversity Hospital BrnoBrnoCzech Republic

Personalised recommendations